Scientists discover molecular brake that limits nerve regeneration
Blocking AHR protein could enhance recovery from nerve and spinal cord injuries
1Key barrier to nerve regeneration identified
Researchers at Mount Sinai have uncovered why damaged nerves struggle to heal. Published in Nature, their study reveals the aryl hydrocarbon receptor (AHR) protein acts as a molecular brake on nerve regeneration. This discovery paves the way for new treatments that could improve recovery from peripheral nerve damage and spinal cord injuries by inhibiting AHR activity.
2The axon regeneration challenge
Axons are nerve cell extensions responsible for signal transmission throughout the nervous system. In adult mammals, their limited regenerative capacity often leads to permanent movement and sensory deficits after injury. The new research provides the first evidence of AHR's role in restricting this regeneration process in damaged neurons.
3Stress management vs repair decision
Senior author Dr. Hongyan Zou explains that injured neurons face a choice between managing cellular stress and rebuilding axons. The AHR protein functions like a brake that prioritizes stress responses over regeneration. When researchers blocked AHR activity, neurons shifted their focus to repair processes, demonstrating improved axon regrowth.
4Promising results in animal models
The study showed that suppressing AHR activity enhanced axon regeneration in mouse models of peripheral nerve damage and spinal cord injury. Treated animals exhibited significant improvements in motor and sensory functions. These findings suggest similar therapeutic approaches might benefit human patients with neurological injuries.
5Protein quality control balance
Mechanistic studies revealed AHR supports proteostasis - the protein quality control system - after injury. While this protective mechanism helps neurons cope with stress, it simultaneously limits production of new proteins needed for axon regrowth. AHR inhibition tips this balance toward regeneration by reducing proteostatic constraints.
6Unexpected role of HIF-1 factor
The research uncovered that AHR inhibition's effects depend on another factor called HIF-1, which regulates genes involved in metabolism and tissue repair. This finding expands potential therapeutic targets by revealing coordinated molecular pathways in nerve regeneration, suggesting multiple points for intervention.
7Toward clinical applications
Several AHR-inhibiting drugs are already in clinical trials for other conditions, potentially accelerating their repurposing for nerve injury treatments. However, researchers emphasize the need to determine optimal dosing and treatment timing for different injury types before human applications can be considered.
8New hope for neurological disorders
The Mount Sinai team continues testing AHR-targeting drugs and gene therapy approaches. Future studies will examine how these strategies affect recovery from spinal cord injury, stroke, and other neurological conditions. This discovery could mark a turning point in treating previously irreversible nerve damage.